Undecimal Bio raises $18 million for RNA medicine delivery

First reported by CTech at · Updated · 2 sources

The Eleven Therapeutics spinout is developing an AI-enabled platform to deliver gene-silencing medicines to specific cells beyond the liver, according to CTech. RNA-based treatments have had their greatest success in the liver, CTech reports, while RuntimeWire says the funding will advance Undecimal's DELiveri platform and renovascular programs.

  • RuntimeWire identifies Yaniv Erlich and Shaul Ilan as the company's co-founders.

Covered by 2 publishers within 2 hours of the first report.

Reporting2

CTech Undecimal Bio raises $18 million Seed to tackle a key obstacle in RNA medicines
RuntimeWire Undecimal raises $18M to move siRNA delivery beyond the liver · RuntimeWire Staff